Astal Laboratories Ltd. (ASTALLTD): Astal Laboratories Share Price Rises 9.34% as Micro Cap Stock Enters Top Gainers

Astal Laboratories rose to Rs 89, up 9.34% today, taking its market capitalisation to Rs 356.52 crore and placing the micro-cap stock among the session’s top gainers.

Astal Laboratories Share Price climbed to Rs 89 on 11 August 2026, up Rs 7.6 or 9.34% from the previous close of Rs 81.4, lifting the company’s market capitalisation to Rs 356.52 crore. The move puts the BSE-listed micro-cap pharmaceutical stock in focus in today’s Stock Market Today setup, especially because it was captured by the PRICE_RISE_THRESHOLD screen.

At a market level, the verified data confirms a strong same-day price rise, a higher intraday high of Rs 89.5 and total traded volume of 27,840 shares on BSE. Turnover stood at Rs 0.25 crore, showing that the move had measurable trading participation even in a relatively small-sized counter. Astal Laboratories Share Price Today therefore stands out not because of an announced company-specific trigger in the supplied data, but because the stock has clearly moved into the Top Gainers Today basket within its category.

For investors searching Astal Laboratories Stock News, the immediate takeaway is straightforward: the stock opened at Rs 83.8, never fell below that level during the session range provided, and advanced to Rs 89.5 before trading at Rs 89. That intraday structure points to firm price action. Univest notes that this kind of move becomes relevant when combined with valuation, profitability and industry context. The next things to monitor are whether price action holds near the day’s upper band, how the company’s valuation compares with pharmaceutical peers, and whether weak return ratios improve over time.

Astal Laboratories Ltd. (ASTALLTD) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 89
Previous Close	Rs 81.4
Today's Change	+Rs 7.6 (+9.34%)
Day Open	Rs 83.8
Day High	Rs 89.5
Day Low	Rs 83.8
Current Volume (BSE)	27,840
BSE Traded Volume	27,840
Combined NSE + BSE Volume	27,840
Turnover	Rs 0.25 crore
Market Capitalisation	Rs 356.52 crore
Market Cap Category	Micro Cap

Astal Laboratories Ltd. (ASTALLTD) traded at Rs 89. versus the previous close of Rs 81.4, a rise of 9.34%. The stock opened at Rs 83.8, reached Rs 89.5, touched Rs 83.8. Reported volume was 27,840.

Astal Laboratories Ltd. (ASTALLTD) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 356.52 crore
P/E Ratio	43.93x
P/B Ratio	1.07x
ROE	0.12%
ROCE	0.16%
EPS	Rs 1.85
Dividend Yield	0%

Astal Laboratories Ltd. was valued at a P/E ratio of 43.93x, a P/B ratio of 1.07x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0.12% and ROCE of 0.16%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 1.85, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Astal Laboratories Fundamental Analysis begins with a mixed picture: the company is a micro-cap business with a market capitalisation of Rs 356.52 crore, a P/E ratio of 43.93 and a P/B ratio of 1.07. Earnings exist, but profitability ratios remain very low, so today’s price rise sits alongside modest underlying return metrics.

On valuation, Astal Laboratories trades at 43.93 times earnings. That is a meaningful figure because it suggests the market is assigning a moderate-to-elevated earnings multiple relative to the company’s current profitability profile. The P/B ratio of 1.07 is much lower than the earnings multiple may imply, which means the market value is only slightly above the accounting equity base. In practical terms, Astal Laboratories Share Price reflects a business that is not heavily priced versus book value, even though its P/E ratio is higher than many lower-growth names.

The profitability side is where the numbers look restrained. Return on equity stands at 0.12, while return on capital employed is 0.16. Those are low absolute readings and they do not yet indicate strong capital efficiency. EPS is Rs 1.85, which shows the company is earnings-positive, but the earnings base remains small relative to the current stock price. Dividend yield is 0, meaning the supplied data does not indicate a current cash payout return through dividends at this price.

For investors reading Astal Laboratories Stock Analysis or Astal Laboratories Financial Results related searches, the key tension is clear. The stock is profitable on a per-share basis, with EPS at Rs 1.85, and the balance-sheet valuation is not stretched on the supplied P/B ratio of 1.07. However, ROE of 0.12 and ROCE of 0.16 show that the business is not yet generating strong returns on shareholder equity or capital employed.

That makes today’s attention more about market action than proven operating strength. Univest would frame Astal Laboratories Share Price as a case where price momentum has become visible faster than financial quality metrics have strengthened. That is why ownership structure, sector positioning and peer comparison matter for a fuller reading of the move.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	43.93x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	1.07x
Benchmark Median P/B	1.8x
Company ROE	0.12%
Benchmark Median ROE	10.59%
Company ROCE	0.16%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 356.52 crore
Benchmark Median Market Cap	Rs 146.99 crore

Astal Laboratories Ltd. (ASTALLTD) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astal Laboratories Ltd. (ASTALLTD) has a P/E ratio of 43.93x, which is above the benchmark median of 25.7x, a difference of +70.93%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astal Laboratories Ltd. (ASTALLTD) has a ROE of 0.12%, which is below the benchmark median of 10.59%, a difference of -98.87%. Astal Laboratories Ltd. (ASTALLTD) has a ROCE of 0.16%, which is below the benchmark median of 12.98%, a difference of -98.77%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Astal Laboratories operates in Healthcare and specifically in Pharmaceuticals & Drugs. Against a same-industry benchmark of 137 companies, the stock’s valuation and profitability profile looks mixed: its P/E of 43.93 sits above the median but below the average, while its P/B of 1.07 is below both the median and average.

The sector benchmark gives useful context for Astal Laboratories Share Price Today. Within the Pharmaceuticals & Drugs universe of 137 companies in the same industry scope, the company P/E is 43.93. The benchmark median P/E is 25.7 and the benchmark average is 69.27, with a very wide range from 3.08 to 3396.3 across 104 companies with P/E data. That places Astal Laboratories above the median valuation on earnings, but still below the industry average, which is lifted by high-multiple outliers.

Price-to-book looks more conservative. Astal Laboratories has a P/B ratio of 1.07, while the benchmark median is 1.8 and the average is 2.49 across 136 companies. The benchmark range stretches from -16.9 to 15.98, so the company’s P/B sits on the lower side of the industry distribution. In other words, Astal Laboratories Share Price is not demanding relative to book value when compared with a large part of its listed peer set.

Profitability is where the contrast sharpens. Company ROE is 0.12 versus an industry median of 10.59 and average of 8.24 across 136 companies. Company ROCE is 0.16 against a median of 12.98 and average of 15.72. These figures place Astal Laboratories well below typical industry profitability levels in the supplied benchmark. Meanwhile, its market capitalisation of Rs 356.52 crore compares with an industry median of Rs 146.99 crore and average of Rs 500.01 crore, with the full range spanning Rs 6.55 crore to Rs 3,032.97 crore.

For readers of Astal Laboratories Latest News and Astal Laboratories Market Cap trends, the sector message is balanced. Univest sees valuation by book value as relatively moderate, valuation by earnings as above the median, and profitability as substantially below industry norms. That combination helps explain why today’s market interest is notable but still requires careful financial context.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Astal Laboratories Ltd. (ASTALLTD) has a P/E ratio of 43.93x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0.12% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 0.16% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Astal Laboratories Ltd. (ASTALLTD) has a market capitalisation of Rs 356.52 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Among listed pharmaceutical peers supplied in the dataset, Astal Laboratories is much smaller by market value, but its valuation and return profile can still be benchmarked. Its P/E of 43.93 is close to some peers, while its ROE of 0.12 and ROCE of 0.16 are materially lower than most comparables shown.

The size gap is the first obvious point. Astal Laboratories has a market capitalisation of Rs 356.52 crore, far below Dishman Carbogen Amcis at Rs 3,032.97 crore, Hikal at Rs 2,799.54 crore, Kwality Pharmaceuticals at Rs 2,707.2 crore, Beta Drugs at Rs 2,631.45 crore and Panacea Biotec at Rs 2,531.49 crore. Even the lower end of the supplied peer list, including Hester Biosciences at Rs 2,057.85 crore and Venus Remedies at Rs 2,068.61 crore, remains several times larger.

On valuation, Astal Laboratories’ P/E of 43.93 is close to NGL Fine-Chem at 44.48 and slightly above Kwality Pharmaceuticals at 40.09. It is lower than Beta Drugs at 66.92 and far lower than Sai Parenteral’s at 181.97, but higher than Venus Remedies at 17.49 and Hester Biosciences at 15.63. That suggests the stock is not the most expensive in the peer group on earnings, but neither is it among the cheapest names with available P/E data.

Its P/B ratio of 1.07 is lower than Hikal at 2.32, Kwality Pharmaceuticals at 9.77, Beta Drugs at 10.59, Panacea Biotec at 8.67, Sai Parenteral’s at 3.36, Solara Active Pharma Sciences at 1.93, NGL Fine-Chem at 6.5, Venus Remedies at 2.96 and Hester Biosciences at 4.68. Only Dishman Carbogen Amcis at 0.76 trades lower on this metric among the listed names shown.

The challenge is returns. Astal Laboratories reports ROE of 0.12 and ROCE of 0.16, which are below Hikal’s 15.22 and 16.15, Kwality’s 28.21 and 26.35, Beta Drugs’ 18.65 and 22.17, NGL Fine-Chem’s 27.9 and 33.91, and even Venus Remedies’ 9.85 and 7.89. Dishman Carbogen Amcis shows negative ROE of -2.89 and ROCE of -0.26, while Panacea Biotec reports ROE of 0 and ROCE of 5.36. Univest therefore reads Astal Laboratories Share Price as relatively light on book-value valuation but still weak on comparative profitability.

Why Investors Are Watching Astal Laboratories

Astal Laboratories Share Price is attracting attention because the stock has delivered a notable same-day gain within the micro-cap segment, while also presenting a valuation profile that looks modest on P/B but demanding relative to its low return ratios. That mix naturally places the company on the radar of traders following Momentum Stocks and investors screening smaller pharmaceutical counters.

• Verified price action: the stock rose 9.34% from Rs 81.4 to Rs 89, after opening at Rs 83.8 and touching Rs 89.5.
• Trading participation: BSE volume, current volume and total volume each stood at 27,840 shares, with turnover of Rs 0.25 crore.
• Valuation context: P/E is 43.93, while P/B is 1.07, creating a mixed valuation signal.
• Profitability context: ROE of 0.12 and ROCE of 0.16 remain well below industry medians.
• Sector position: the company operates in Healthcare, specifically Pharmaceuticals & Drugs, within a 137-company same-industry benchmark.

What investors may monitor next is whether Astal Laboratories Share Price continues to hold near the day’s upper band, whether valuation remains supported by earnings growth over time, and how the stock compares with sector profitability leaders. Univest also sees the industry benchmark as important because the company’s low return profile stands out even after today’s move.

About Astal Laboratories

Astal Laboratories Ltd. is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. That places the company in one of the most closely tracked parts of the Indian Stock Market, where investors often compare business quality through earnings multiples, return ratios and market-cap positioning.

Based on the verified classification in the supplied data, Astal Laboratories operates in the pharmaceutical ecosystem rather than in a diversified industrial or consumer category. For readers searching Astal Laboratories Company News or Astal Laboratories NSE and BSE references, the main context is that this is a micro-cap healthcare company with a current market capitalisation of Rs 356.52 crore. Within its same-industry benchmark set of 137 listed companies, it sits above the median market cap of Rs 146.99 crore but below the average of Rs 500.01 crore.

That positioning matters because smaller pharmaceutical companies often draw attention when sharp price rises appear alongside measurable earnings, sector relevance and comparatively low book-value multiples. Astal Laboratories currently trades at a P/E of 43.93 and a P/B of 1.07, while reporting EPS of Rs 1.85. Its return profile, with ROE at 0.12 and ROCE at 0.16, shows that the business remains in an early or modest profitability phase compared with many established peers.

In short, Astal Laboratories is best understood as a listed micro-cap pharma company whose current market interest is being driven by visible price action, while its broader investment profile still depends on how profitability metrics evolve within the Healthcare and Pharmaceuticals & Drugs space.

Track Astal Laboratories Share Price on Univest

Use Astal Laboratories Ltd. (ASTALLTD) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Astal Laboratories Share Price more closely can track the stock on Univest for live market movement, technical snapshots, valuation ratios and broader market context. Astal Laboratories Share Price Today is especially relevant after a sharp one-day move because follow-through, volume behaviour and sector comparison often become more important after the initial rise.

On Univest, users can monitor share price changes, market capitalisation, P/E ratio, P/B ratio, ROE, ROCE, EPS, dividend yield, 52-week levels, shareholding pattern updates when available and broader market insights. For readers looking at Astal Laboratories Stock News, Astal Laboratories Share Price Live or Astal Laboratories Shareholding Pattern related searches, keeping the stock on a watchlist can help organise verified data points in one place without relying on speculation.

Frequently Asked Questions

Why is Astal Laboratories Share Price rising today?

Ans. Astal Laboratories Share Price rose because the stock gained 9.34% in the current session, moving from the previous close of Rs 81.4 to Rs 89. The supplied data confirms the price event and places the micro-cap stock among today’s top.

What is Astal Laboratories Share Price Today?

Ans. Astal Laboratories Share Price Today is Rs 89 based on the supplied market data. The stock opened at Rs 83.8, touched a high of Rs 89.5, and remained well above the previous close of Rs 81.4 during the session.

How much did Astal Laboratories stock gain today?

Ans. Astal Laboratories stock gained Rs 7.6 in absolute terms and 9.34% in percentage terms. That rise took the share price from Rs 81.4 to Rs 89, making it one of the more visible micro-cap price rises today.

What does today’s trading range show for Astal Laboratories?

Ans. The day’s trading range ran from Rs 83.8 to Rs 89.5, with the opening price and day low both at Rs 83.8. That indicates the stock held above the previous close and spent the session with upward price action.

What is the market capitalisation of Astal Laboratories?

Ans. Astal Laboratories has a market capitalisation of Rs 356.52 crore. In the supplied same-industry benchmark of 137 Pharmaceuticals & Drugs companies, that is above the median market cap of Rs 146.99 crore but below the average of Rs 500.01 crore.

Is Astal Laboratories expensive based on P/E and P/B?

Ans. Astal Laboratories trades at a P/E of 43.93 and a P/B of 1.07. Its P/E is above the industry median of 25.7 but below the average of 69.27, while its P/B is below both the median 1.8 and average 2.49.

How profitable is Astal Laboratories compared with its industry?

Ans. Astal Laboratories reports ROE of 0.12 and ROCE of 0.16. Both are below the same-industry medians of 10.59 and 12.98 respectively, showing that profitability remains much weaker than the broader Pharmaceuticals & Drugs benchmark in the supplied data.

What is Astal Laboratories EPS and dividend yield?

Ans. Astal Laboratories has EPS of Rs 1.85 and a dividend yield of 0. EPS indicates the earnings attributable to each share, while the zero dividend yield shows the supplied data does not reflect a current payout return at this price.

Which sector and industry does Astal Laboratories belong to?

Ans. Astal Laboratories belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That industry benchmark in the supplied data covers 137 companies, giving investors a useful comparison set for valuation, profitability and market-cap context.

How does Astal Laboratories compare with listed pharma peers?

Ans. Astal Laboratories is much smaller than peers such as Hikal, Kwality Pharmaceuticals and Beta Drugs by market cap. Its P/B of 1.07 is lower than most supplied peers, but its ROE of 0.12 and ROCE of 0.16 trail many comparables.